Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31985
Title: Using PSMA imaging for prognostication in localized and advanced prostate cancer.
Austin Authors: Roberts, Matthew J;Maurer, Tobias;Perera, Marlon ;Eiber, Matthias;Hope, Thomas A;Ost, Piet;Siva, Shankar;Hofman, Michael S;Murphy, Declan G;Emmett, Louise;Fendler, Wolfgang P
Affiliation: Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Martini-Klinik Prostate Cancer Center, Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Surgery
Department of Nuclear Medicine, Technical University of Munich, Munich, Germany.
Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
Department of Radiation Oncology, Iridium Network, GZA Ziekenhuizen, Antwerp, Belgium.
Peter MacCallum Cancer Centre, Radiation Oncology, Parkville, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, Melbourne University, Parkville, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, Melbourne University, Parkville, Victoria, Australia.
Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.
Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany.
Issue Date: Jan-2023
Date: 2022
Publication information: Nature Reviews. Urology 2023; 20(1)
Abstract: The use of prostate-specific membrane antigen (PSMA)-directed applications in modern prostate cancer management has evolved rapidly over the past few years, helping to establish new treatment pathways and provide further insights into prostate cancer biology. However, the prognostic implications of PSMA-PET have not been studied systematically, owing to rapid clinical implementation without long follow-up periods to determine intermediate-term and long-term oncological outcomes. Currently available data suggest that traditional prognostic factors and survival outcomes are associated with high PSMA expression (both according to immunohistochemistry and PET uptake) in men with localized and biochemically recurrent disease. Treatment with curative intent (primary and/or salvage) often fails when PSMA-positive metastases are present; however, the sensitivity of PSMA-PET in detecting all metastases is poor. Low PSMA-PET uptake in recurrent disease is a favourable prognostic factor; however, it can be associated with poor prognosis in conjunction with high 18F-fluorodeoxyglucose uptake in metastatic castration-resistant prostate cancer. Clinical trials embedding PSMA-PET for guiding management with reliable oncological outcomes are needed to support ongoing clinical use.
URI: https://ahro.austin.org.au/austinjspui/handle/1/31985
DOI: 10.1038/s41585-022-00670-6
ORCID: 0000-0003-0552-7402
0000-0002-5660-7691
0000-0002-1138-6389
0000-0002-2203-4848
0000-0002-7500-5899
Journal: Nature Reviews. Urology
Start page: 23
End page: 47
PubMed URL: 36473945
ISSN: 1759-4820
Type: Journal Article
Subjects: Prostatic Neoplasms/pathology
Prostate/pathology
Positron Emission Tomography Computed Tomography/methods
Positron-Emission Tomography/methods
Appears in Collections:Journal articles

Show full item record

Page view(s)

32
checked on Apr 19, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.